A Randomized, Controlled Trial of an Aerosolized Vaccine against Measles

A more convenient delivery system may facilitate increased global use of measles vaccine. In this randomized, controlled trial involving more than 2000 children in India, the immunogenicity of aerosolized vaccine was inferior to that of vaccine delivered subcutaneously. The Global Vaccine Action Plan aims to eliminate measles from at least five World Health Organization (WHO) regions by 2020. 1 A safe and effective injectable measles vaccine has been widely available since 1963, 2 and intensified efforts between 2000 and 2010 reduced measles-related deaths by 74%. 3 Nevertheless, major outbreaks continue, particularly in resource-poor countries that lack investment in health care systems and the health service infrastructure. In these countries, immunization coverage through routine services and mass campaigns remains low. 4 New approaches to measles vaccination could contribute to reaching elimination goals, particularly if they increase coverage, can be administered by people without . . .